Scholarlink

Purpose <p>The Scottish Inflammatory Prognostic Score (SIPS), derived from serum albumin and neutrophil count integrates inflammatory and nutritional status. However, its prognostic role in advanced non–small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors remains unclear.</p> Methods <p>This multicenter, retrospective study included 816 patients with advanced or metastatic NSCLC who received nivolumab following platinum-based chemotherapy between January 2015 and January 2025 at 19 oncology centers in Turkey. The SIPS was calculated at baseline by assigning one point each for albumin &lt; 35&#xa0;g/L and neutrophil count &gt; 7.5 × 10⁹/L, classifying patients as favorable (0), intermediate (1), or poor (2). Progression-free survival (PFS) and overall survival (OS) were estimated using Kaplan–Meier analysis and compared using the log-rank test. Cox regression models were used to identify independent prognostic factors.</p> Results <p>The median OS decreased across the SIPS groups: 15.0 months (95% CI 12.9–17.1), 8.0 months (95% CI 5.3–10.7), and 5.0 months (95% CI 3.5–6.5) for the favorable, intermediate, and poor groups, respectively (<i>p</i> &lt; 0.001). The median PFS was 7.0, 4.0, and 2.0 months (<i>p</i> &lt; 0.001). In the multivariate analysis, SIPS remained independently associated with both OS (HR = 3.19, 95% CI 1.90–5.35, <i>p</i> &lt; 0.001) and PFS (HR = 3.02, 95% CI 1.89–4.84, <i>p</i> &lt; 0.001).</p> Conclusions <p>Baseline SIPS is a simple, cost-effective, and independent prognostic biomarker in nivolumab-treated NSCLC. Prospective studies are needed to validate these findings and evaluate its integration with other markers to improve clinical risk stratification and may be useful for prognostic assessment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prognostic value of the Scottish Inflammatory Prognostic Score in advanced NSCLC treated with second-line nivolumab

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月21日

查看全文
  • Erdem Kolemen,
  • Kazım Uygun,
  • Devrim Çabuk,
  • Mustafa Erman,
  • Saadettin Kılıçkap,
  • Tolga Köseci,
  • Duygu Bayır,
  • Oktay Bozkurt,
  • Deniz Can Güven,
  • Hacer Demir,
  • Muslih Urun,
  • Sedat Yıldız,
  • Teoman Sakalar,
  • Nargiz Majidova,
  • Emel Mutlu Özkan,
  • Cengiz Akosman,
  • Muhammet Cengiz,
  • Mustafa Ersoy,
  • Elif Şahin,
  • Pervin Can Sancı,
  • Ayşe Nuransoy Cengiz,
  • Gözde Ağdaş,
  • Erkam Kocaaslan,
  • Ezgi Türkoğlu,
  • Sedat Yıldırım,
  • Berrak Mermit Erçek,
  • Anıl Karakayalı,
  • Hayati Arvas,
  • Mehmet Mutlu Kıdı,
  • Sedat Biter,
  • Havva Yeşil Cinkir,
  • Latif Karahan,
  • Aslıhan Ezgi Apaydın Rollas,
  • Umut Kefeli

摘要

Purpose

The Scottish Inflammatory Prognostic Score (SIPS), derived from serum albumin and neutrophil count integrates inflammatory and nutritional status. However, its prognostic role in advanced non–small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors remains unclear.

Methods

This multicenter, retrospective study included 816 patients with advanced or metastatic NSCLC who received nivolumab following platinum-based chemotherapy between January 2015 and January 2025 at 19 oncology centers in Turkey. The SIPS was calculated at baseline by assigning one point each for albumin < 35 g/L and neutrophil count > 7.5 × 10⁹/L, classifying patients as favorable (0), intermediate (1), or poor (2). Progression-free survival (PFS) and overall survival (OS) were estimated using Kaplan–Meier analysis and compared using the log-rank test. Cox regression models were used to identify independent prognostic factors.

Results

The median OS decreased across the SIPS groups: 15.0 months (95% CI 12.9–17.1), 8.0 months (95% CI 5.3–10.7), and 5.0 months (95% CI 3.5–6.5) for the favorable, intermediate, and poor groups, respectively (p < 0.001). The median PFS was 7.0, 4.0, and 2.0 months (p < 0.001). In the multivariate analysis, SIPS remained independently associated with both OS (HR = 3.19, 95% CI 1.90–5.35, p < 0.001) and PFS (HR = 3.02, 95% CI 1.89–4.84, p < 0.001).

Conclusions

Baseline SIPS is a simple, cost-effective, and independent prognostic biomarker in nivolumab-treated NSCLC. Prospective studies are needed to validate these findings and evaluate its integration with other markers to improve clinical risk stratification and may be useful for prognostic assessment.